REPLACEMENT HORMONE THERAPY IN GONADAL DY SGENESIS
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1975.tb00657.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b)
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 82, Issue 5, pages 412–416, May 1975
Additional Information
How to Cite
Dewhurst, C. J., de Koos, E. B. and Haines, R. M. (1975), REPLACEMENT HORMONE THERAPY IN GONADAL DY SGENESIS. BJOG: An International Journal of Obstetrics & Gynaecology, 82: 412–416. doi: 10.1111/j.1471-0528.1975.tb00657.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Abstract
- References
- Cited By
Summary
Curettage carried out during the third week of treatment with ethinyl oestradiol in 14 patients with gonadal dysgenesis showed cystic glandular hyperplasia in seven patients with some hyperplastic changes in one other. One of these seven patients developed a large endometrial polyp and in one atypical changes were found in the hyperplastic endometrium. In seven patients treated by an oestrogen-progestogen combination normal secretory endometrium was seen in five, proliferative change only in one (thought to be due to incorrect timing of the curettage) and a small proliferative polyp in association with secretory endometrium elsewhere in the uterus in the seventh. In view of these changes and report of adenocarcinoma of the endometrium in patients with gonadal dysgenesis treated with oestrogens alone it is suggested that a regime of low dose oestrogen therapy for 21 days accompanied by a progestogen on days 15 to 21 is preferable to oestrogens alone.

1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)